Baicalin reduces inflammation to inhibit lung cancer via targeting SOCS1/NF- κ B/STAT3 axis

Inflammation affects several aspects of lung cancer progression including cell proliferation, metastasis, apoptosis, angiogenesis, and drug resistance. Baicalin, an active component of Scutellaria baicalensis Georgi, exhibits anticancer activity in various cancers. However, the effects of baicalin on lung cancer and the underlying molecular mechanisms remain largely unknown. This study is to explore the effect and mechanism of baicalin on lung cancer cell A549 and urethaneinduced mouse lung cancer. A cell viability assay, colony formation assay, wound healing assay, acridine orange/ethidium bromide (AO/EB) staining assay, Western blot assay, urethane -induced mouse lung cancer model, hematoxylin and eosin (HE) staining, immunohistochemistry (IHC), and ELISA assay were performed to investigate the effects of baicalin on lung cancer in vitro and in vivo . Network pharmacology analysis, molecular docking, gene silencing assays, and LPS-induced inflammation model were utilized to explore the molecular mechanisms underlying the effect of baicalin on lung cancer. Baicalin showed significant anti -proliferative, anti -migratory, antiinflammatory and pro-apoptotic effects in vitro ; it also inhibited the progression of urethaneinduced mouse lung cancer in vivo . Mechanistically, suppressor of cytokine signaling 1 (SOCS1) was the key determinant for baicalin-induced inhibition of lung cancer. Baicalin increased SOCS1 expression to inactivate the NF- kappa B/STAT3 pathway to inhibit lung cancer in vitro and in vivo . Taken together, baicalin reduces inflammation to inhibit lung cancer via targeting SOCS1/NF- kappa B/ STAT3 axis, providing a prospective compound and novel target for lung cancer treatment.